The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity

Background: Research on employee care partners of patients with multiple sclerosis (MS) is limited. Objectives: The clinical and economic impact on employee care partners was evaluated by MS disease severity. Methods: Employees with spouses/domestic partners with MS from the Workpartners database (Jan. 1, 2010–Dec. 31, 2019) were eligible if: spouse/partner had at least 3 MS-related (ICD-9-CM/ICD-10-CM:340.xx/G35) inpatient/outpatient/disease-modifying therapy claims within 1 year (latest claim = index date); 6-month pre-index/1-year post-index enrollment; and age 18 to 64 years. Employee care partners’ demographic/clinical characteristics and direct/indirect costs were compared across predetermined MS severity categories. Logistic and generalized linear regression modeled the costs. Results: Among 1041 employee care partners of patients with MS, 358 (34.4%) patients had mild MS, 491 (47.2%) moderate, and 192 (18.4%) severe. Mean (standard error [SE]) employee care partner age was 49.0 (0.5) for patients with mild disease, 50.5 (0.4) for moderate, 51.7 (0.6) for severe; percent female care partners was 24.6% [2.3%] mild, 19.8% [1.8%] moderate, 27.6% [3.2%] severe; and mean care partner Charlson Comorbidity Index scores 0.28 (0.05) mild, 0.30 (0.04) moderate, 0.27 (0.06) severe. More care partners of patients with moderate/severe vs mild MS had hyperlipidemia (32.6%/31.8% vs 21.2%), hypertension (29.5%/29.7% vs 19.3%), gastrointestinal disease (20.8%/22.9% vs 13.1%), depression (9.2%/10.9% vs 3.9%), and anxiety 10.6%/8.9% vs 4.2%). Adjusted mean medical costs were greater for employee care partners of patients with moderate vs mild/severe disease (P<.001). Pharmacy costs (SE) were lower for employee care partners of mild vs severe/moderate patients (P<.005). Sick leave costs (SE) were greater for employee care partners of mild/severe vs moderate patients (P<.05). Discussion: Employee care partners of patients with moderate/severe vs mild MS had more comorbidities (ie, hypertension, gastrointestinal disease, depression, and anxiety) and higher pharmacy costs. Employee care partners of patients with moderate vs mild/severe MS had higher medical and lower sick leave costs. Treatment strategies that improve patient outcomes may reduce employee care partner burden and lower costs for employers in some instances. Conclusions: Comorbidities and direct/indirect costs of employees whose spouses/partners have MS were considerable and varied with MS severity.

[1]  G. Pardo,et al.  The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis , 2022, Journal of health economics and outcomes research.

[2]  Daniel M. Hartung,et al.  The Economic Burden of Multiple Sclerosis in the United States , 2022, Neurology.

[3]  J. Chojdak-Łukasiewicz,et al.  Adherence to Therapy in Patients with Multiple Sclerosis—Review , 2022, International journal of environmental research and public health.

[4]  P. Maguire,et al.  Caregiver Burden in Multiple Sclerosis: Recent Trends and Future Directions , 2020, Current Neurology and Neuroscience Reports.

[5]  P. Sørensen,et al.  Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  M. Pereira,et al.  Quality of life in patients with multiple sclerosis: A study with patients and caregivers. , 2019, Disability and health journal.

[7]  H. Middelkoop,et al.  Caregiver strain among life partners of persons with mild disability due to relapsing-remitting multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[8]  P. Maguire,et al.  Beyond care burden: associations between positive psychological appraisals and well-being among informal caregivers in Europe , 2019, Quality of Life Research.

[9]  C. Isaac,et al.  The Relational Impact of Multiple Sclerosis: An Integrative Review of the Literature Using a Cognitive Analytic Framework , 2017, Journal of Clinical Psychology in Medical Settings.

[10]  H. Zucker,et al.  A Call to Preventive Action by Health Care Providers and Policy Makers to Support Caregivers , 2016, Preventing chronic disease.

[11]  Paolo Confalonieri,et al.  Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis , 2016, Journal of Neurological Sciences.

[12]  A. Lutterotti,et al.  Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study , 2016, PloS one.

[13]  R. Marrie,et al.  Care Partners and Multiple Sclerosis: Differential Effect on Men and Women. , 2015, International journal of MS care.

[14]  É. Bayen,et al.  Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis , 2015, Behavioural neurology.

[15]  Deborah M. Miller,et al.  Who is Taking Care of the Caregiver? , 2015, Journal of patient experience.

[16]  M. Duh,et al.  Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis , 2015, Journal of medical economics.

[17]  Patricia Eckardt,et al.  Caregivers of Older Persons With Multiple Sclerosis: Determinants of Health-Related Quality of Life , 2015, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[18]  Lynda Hillman Caregiving in multiple sclerosis. , 2013, Physical medicine and rehabilitation clinics of North America.

[19]  A. Goren,et al.  Self-reported burden among caregivers of patients with multiple sclerosis. , 2012, International journal of MS care.

[20]  Frauke Zipp,et al.  Neurodegeneration in multiple sclerosis: novel treatment strategies , 2012, Expert review of neurotherapeutics.

[21]  D. Sobieraj,et al.  Dosing frequency and medication adherence in chronic disease. , 2012, Journal of managed care pharmacy : JMCP.

[22]  H. Birnbaum,et al.  Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US , 2012, Journal of medical economics.

[23]  M. Boakye,et al.  Socioeconomic Trends in Hospitalization for Multiple Sclerosis , 2010, Neuroepidemiology.

[24]  F. Patti Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence , 2010, Patient preference and adherence.

[25]  M. Dubinsky,et al.  Effect of medication dosing frequency on adherence in chronic diseases. , 2009, The American journal of managed care.

[26]  H. Birnbaum,et al.  Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs* , 2009, Current medical research and opinion.

[27]  D. Aarsland,et al.  Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  H. Young,et al.  Is Caregiving a Risk Factor for Illness? , 2004 .

[29]  E. Oster,et al.  Cost of Stress Urinary Incontinence , 2004, PharmacoEconomics.

[30]  H. Birnbaum,et al.  The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US , 2012, PharmacoEconomics.

[31]  J. Opara,et al.  Burden and quality of life in caregivers of persons with multiple sclerosis. , 2012, Neurologia i neurochirurgia polska.

[32]  E. Oster,et al.  Cost of stress urinary incontinence: a claims data analysis. , 2004, PharmacoEconomics.